Literature DB >> 30868551

Epidemiology and Clinical Manifestations of Immune Thrombocytopenia.

Rahil Kohli1, Shruti Chaturvedi1.   

Abstract

Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000 patient-years, which increases with age and has a slight female preponderance. ITP is termed acute, persistent or chronic when its duration is <3 months, 3 to 12 months and >12 months, respectively. In this narrative review, we discuss the clinical manifestations of ITP in children and adults. ITP is asymptomatic in some patients; however, when present, bleeding is the most common symptom and can be mild as in petechiae, purpura and epistaxis, or severe and even life threatening in cases of intracranial haemorrhage, and massive gastrointestinal or urinary tract bleeding. A platelet count <10-20 × 109/L, advanced age and prior minor bleeding are risk factors for major bleeding, which is also more common in the months following a new diagnosis of acute ITP. Fatigue and impaired health-related quality of life are also manifestations of ITP that often improve with treatment and improvement in platelet counts. Over long-term follow-up, ITP is also associated with an increased risk of venous and arterial thromboembolism, haematologic malignancy and overall mortality than the general population. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30868551     DOI: 10.1055/s-0039-1683416

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  4 in total

1.  [Coagulation diagnostics in the clinical routine-part 2 : Monitoring of anticoagulation treatment, new-onset thrombocytopenia and thrombophilia].

Authors:  Michael Metze; Martin Platz; Christian Pfrepper; Sirak Petros
Journal:  Inn Med (Heidelb)       Date:  2022-05-19

2.  Use of bioinformatic analyses in identifying characteristic genes and mechanisms active in the progression of idiopathic thrombocytopenic purpura in individuals with different phenotypes.

Authors:  Mengyi Zhang; Binhan Guo
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

3.  Correspondence on "Immune thrombocytopenia in 2 healthy young women after the Pfizer-BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination".

Authors:  Won Sriwijitalai; Viroj Wiwanitkit
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-01-15

4.  A rare case of pediatric immune thrombocytopenia with secondary antiphospholipid syndrome in Korea.

Authors:  Eun Ji Mun; Ye Jee Shim; Heung Sik Kim
Journal:  Blood Res       Date:  2022-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.